MENU
NEWSLETTERS
MENU
SECTIONS
OTHER
CLASSIFIEDS
CONTACT US / FAQ
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Intra-Cellular Therapies Inc. - Common Stock (NQ:ITCI)

131.87 UNCHANGED
Last Price Updated: 4:00 PM EDT, Apr 1, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Intra-Cellular Therapies Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >
News headline image
23 Stocks Moving in Tuesday's Pre-Market Session ↗
Gainers Allena Pharmaceuticals, Inc. (NASDAQ: ALNA) rose 62.1% to $1.05 in pre-market trading as the company issued a clinical and corporate update. NeuroBo Pharmaceuticals, Inc... 
Via Benzinga
News headline image
IntraCellular Seeks To Raise $400M Via Equity To Fund Commercialization Of Schizophrenia Med ↗
Intra-Cellular Therapies Inc (NASDAQ: ITCI) commenced an underwritten public offering of $400 million of shares. Underwriters have an option to purchase up to an... 
Via Benzinga
News headline image
A Peek Into The Markets: US Stock Futures Up Ahead Of Manufacturing Report ↗
Pre-open movers U.S. stock futures traded higher in early pre-market trade after the Dow Jones and S&P 500 closed at fresh highs on the first trading day of new year.... 
Via Benzinga
News headline image
5 Stocks To Watch For January 4, 2022 ↗
Some of the stocks that may grab investor focus today are: Wall Street expects SMART Global Holdings, Inc. (NASDAQ: SGH) to report quarterly earnings at $2.00 per share on... 
Via Benzinga
News headline image
Analyst Ratings For Intra-Cellular Therapies ↗
Within the last quarter, Intra-Cellular Therapies (NASDAQ:ITCI) has observe... 
Via Benzinga
News headline image
The Week Ahead In Biotech (Aug. 8-14): Jazz Pharma FDA Decision, Earnings Deluge and IPOs In The Spotlight ↗
Biopharma stocks ended higher for the week ending Aug. 6, as the sector latched on to the optimism that was evident in the broader markets. Earnings continued to flow in,... 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Monday's After-Market Session ↗
Gainers Indaptus Therapeutics (NASDAQ:INDP 
Via Benzinga
The Global Breast Cancer Treatment Market Expected To Reach $34.06 Billion By End Of 2026
Palm Beach, FL – December 21, 2021 – FinancialNewsMedia.com News Commentary – Breast cancer is cancer that develops in the breast tissue. Breast cancer signs include the formation of a lump in the... 
Via FinancialNewsMedia
News headline image
38 Stocks Moving In Monday's Mid-Day Session ↗
Gainers Society Pass Incorporated (NASDAQ: SOPA) shares jumped 120.9% to $7.31 after the company reported addition to the Russell 2000 Index. Can-Fite BioPharma Ltd. (NYSE: CANF... 
Via Benzinga
News headline image
65 Biggest Movers From Yesterday ↗
Gainers Society Pass Incorporated (NASDAQ: SOPA) shares climbed 240.2% to close at $11.26 on Monday after the company reported addition to the Russell 2000 Index. Bluerock... 
Via Benzinga
News headline image
FDA Approves Intra-Cellular's Antipsychotic For Bipolar Depression ↗
The FDA has approved Intra-Cellular Therapies Inc (NASDAQ: ITCI) Caplyta for depressive episodes associated with bipolar I or II disorder in adults. The approval... 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Monday's Pre-Market Session ↗
Gainers Intra-Cellular Therapies (NASDAQ:ITCI) stock rose 18.79% to $46.52 during Monday's pre-market session. The market value of their outstanding shares is at $3.7... 
Via Benzinga
News headline image
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday ↗
The weekend break is over and that means it's time to get back to work with the biggest pre-market stock movers for Monday! 
Via InvestorPlace
News headline image
The Daily Biotech Pulse: Genfit Spikes On Liver Disease Drug Licensing Deal, Lyell Gets Nod For Solid Tumor Study, Decision-Day For Intra-Cellular, Argenx ↗
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Merck Announces Publication Of Positive Data From Late-Stage Study Of Oral... 
Via Benzinga
News headline image
The Week Ahead In Biotech (Dec. 12-18): Hematology Conference Presentations, FDA Decisions For Calliditas, Argenx, Intra-Cellular & Eagle Pharma And More ↗
Biotech stocks closed out the week ending Dec. 10 with modest losses as investors moved money out of defensives and into risky bets amid the broader market rebound. Multiple... 
Via Benzinga
News headline image
Attention Biotech Investors: Mark Your Calendar For December PDUFA Dates ↗
A majority of verdicts handed down by the FDA in November were positive. Three new molecular entities were approved during the month, taking the total number of NME approvals for... 
Via Benzinga
News headline image
Looking Into Intra-Cellular Therapies's Return On Capital Employed ↗
Benzinga Pro data, Intra-Cellular Therapies (NASDAQ:ITCI) reported Q3 sales of $22.21 million. Earnings fell to a loss of $77.32 million, resulting in a 11.83% decrease from last... 
Via Benzinga
News headline image
Intra-Cellular Therapies inc (ITCI) Q3 2021 Earnings Call Transcript ↗
ITCI earnings call for the period ending September 30, 2021. 
Via The Motley Fool
Topics Earnings
News headline image
Intra-Cellular Therapies: Q3 Earnings Insights ↗
Intra-Cellular Therapies (NASDAQ:ITCI) reported its Q3 earnings results on Tuesday, November 9, 2021 at 08:00 AM. Here's what investors need to know about the... 
Via Benzinga
Two Trillion-Dollar Industries Being Transformed By Tech
FN Media Group Presents Oilprice.com Market Commentary London – October 20, 2021 – Big money is pouring into two disruptive segments in two of the world’s biggest industries – healthcare and energy.... 
Via FinancialNewsMedia
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For September 23, 2021 ↗
Upgrades Barclays upgraded the previous rating for Warner Music Group Corp (NASDAQ: 
Via Benzinga
News headline image
Looking Into Intra-Cellular Therapies's Return On Capital Employed ↗
Intra-Cellular Therapies (NASDAQ:ITCI) brought in sales totaling $20.05 million during Q2 according to data provided by Benzinga Pro. However, earnings decreased 29.92%, resulting... 
Via Benzinga
News headline image
Why Intra-Cellular Therapies Was Weak This Week ↗
The company's second-quarter net loss was a bit deeper than analysts expected. 
Via The Motley Fool
News headline image
Intra-Cellular Therapies inc (ITCI) Q2 2021 Earnings Call Transcript ↗
ITCI earnings call for the period ending June 30, 2021. 
Via The Motley Fool
Topics Earnings
News headline image
Intra-Cellular Therapies: Q2 Earnings Insights ↗
Shares of Intra-Cellular Therapies (NASDAQ:ITCI) were unchanged after the company reported Q2 results. Quarterly Results Earnings per share rose 11.46% over the past year... 
Via Benzinga
News headline image
Pandemic Fallout: 6 Mental Health Stocks To Watch ↗
One of the most devastating long-term impacts of the COVID-19 pandemic may be the toll it has taken on people’s mental health. The next globa... 
Via Benzinga
News headline image
Looking Into Intra-Cellular Therapies's Return On Capital Employed ↗
During Q1, Intra-Cellular Therapies (NASDAQ:ITCI) brought in sales totaling $15.88 million. However, earnings decreased 13.23%, resulting in a loss of $53.22 million. In Q4, Intra... 
Via Benzinga
News headline image
Earnings Scheduled For August 9, 2021 ↗
Companies Reporting Before The Bell • Privia Health Group (NASDAQ:PRVA) is projected to report quarterly loss at $1.57 per share on revenue of $215.17 million. •... 
Via Benzinga
News headline image
The Daily Biotech Pulse: Lilly Spikes On Alzheimer's Drug Regulatory Filing Plan, Applied Genetics, Arcus Issue Data Readouts, Adcom Test Awaits Incyte, Monte Rosa Prices IPO ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 23) AngioDynamics, Inc. (NASDAQ... 
Via Benzinga
News headline image
The Daily Biotech Pulse: Gemini Sinks On Data, Amgen's Migraine Drug Approved In Japan, Liver Congress Gets Underway ↗
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 22) AngioDynamics, Inc. (NASDAQ... 
Via Benzinga
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story